234 related articles for article (PubMed ID: 30139925)
1. Single-cell heterogeneity in Sézary syndrome.
Buus TB; Willerslev-Olsen A; Fredholm S; Blümel E; Nastasi C; Gluud M; Hu T; Lindahl LM; Iversen L; Fogh H; Gniadecki R; Litvinov IV; Persson JL; Bonefeld CM; Geisler C; Christensen JP; Krejsgaard T; Litman T; Woetmann A; Ødum N
Blood Adv; 2018 Aug; 2(16):2115-2126. PubMed ID: 30139925
[TBL] [Abstract][Full Text] [Related]
2. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
[TBL] [Abstract][Full Text] [Related]
3. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
4. Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome.
Vadivel CK; Willerslev-Olsen A; Namini MRJ; Zeng Z; Yan L; Danielsen M; Gluud M; Pallesen EMH; Wojewoda K; Osmancevic A; Hedebo S; Chang YT; Lindahl LM; Koralov SB; Geskin LJ; Bates SE; Iversen L; Litman T; Bech R; Wobser M; Guenova E; Kamstrup MR; Ødum N; Buus TB
Blood; 2024 Apr; 143(15):1496-1512. PubMed ID: 38170178
[TBL] [Abstract][Full Text] [Related]
5. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
[TBL] [Abstract][Full Text] [Related]
7. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.
Stephen S; Morrissey KA; Benoit BM; Kim EJ; Vittorio CC; Nasta SD; Showe LC; Wysocka M; Rook AH
Am J Hematol; 2012 Feb; 87(2):226-8. PubMed ID: 22189940
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
Kelly-Sell MJ; Kim YH; Straus S; Benoit B; Harrison C; Sutherland K; Armstrong R; Weng WK; Showe LC; Wysocka M; Rook AH
Am J Hematol; 2012 Apr; 87(4):354-60. PubMed ID: 22367792
[TBL] [Abstract][Full Text] [Related]
10. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy SA
Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
[TBL] [Abstract][Full Text] [Related]
12. Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.
Chung JS; Shiue LH; Duvic M; Pandya A; Cruz PD; Ariizumi K
Blood; 2011 Mar; 117(12):3382-90. PubMed ID: 21252093
[TBL] [Abstract][Full Text] [Related]
13. Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome.
Najidh S; Tensen CP; van der Sluijs-Gelling AJ; Teodosio C; Cats D; Mei H; Kuipers TB; Out-Luijting JJ; Zoutman WH; van Hall T; Orfao A; Almeida J; van Dongen JJM; Vermeer MH
Blood; 2021 Dec; 138(24):2539-2554. PubMed ID: 34314480
[TBL] [Abstract][Full Text] [Related]
14. Sézary Syndrome, recent biomarkers and new drugs.
Cristofoletti C; Narducci MG; Russo G
Chin Clin Oncol; 2019 Feb; 8(1):2. PubMed ID: 30525758
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G
Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744
[TBL] [Abstract][Full Text] [Related]
16. Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells.
Chebly A; Prochazkova-Carlotti M; Idrissi Y; Bresson-Bepoldin L; Poglio S; Farra C; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Front Oncol; 2021; 11():775253. PubMed ID: 34765562
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
18. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of T-plastin in Sezary cells.
Su MW; Dorocicz I; Dragowska WH; Ho V; Li G; Voss N; Gascoyne R; Zhou Y
Cancer Res; 2003 Nov; 63(21):7122-7. PubMed ID: 14612505
[TBL] [Abstract][Full Text] [Related]
20. Single TCR-Vβ2 evaluation discloses the circulating T cell clone in Sezary syndrome: one family fits all!
Scala E; Abeni D; Pomponi D; Russo N; Russo G; Narducci MG
Arch Dermatol Res; 2015 Aug; 307(6):487-93. PubMed ID: 25733488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
